X
Gilead joins protein degradation drive with Nurix deal
https://pharmaphorum.com/news/gilead-joins-protein-degradation-drive-with-nurix-deal/
immuno-oncology
Immuno-Oncology 2018 News: MHRA Interview and New Speaker ImmuneBiotech AB Announced
Just Over 1 Week Until Immuno-Oncology 2018 Commences
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conference
MHRA, Pfizer & Autolus Sign Up for Immuno-Oncology 2018
Less than 4 Weeks until Immuno-Therapy Experts Gather at the Immuno-Oncology Conference
Less than 4 Weeks until Immuno-Oncology Conference
Invitation from Chair of this year’s Immuno-Oncology Conference in London
Invitation from Chair of Immuno-Oncology Conference
Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research
Challenges facing Immuno-Oncology industry
Strategic Competitive Intelligence and the role of the Microbiome in Immuno-Oncology
Immuno-Oncology Conference – London – September